Home > Publications database > The effect of risperidone on reward‐related brain activity is robust to drug‐induced vascular changes > print

001     893882
005     20210810182041.0
024 7 _ |a 10.1002/hbm.25400
|2 doi
024 7 _ |a 1065-9471
|2 ISSN
024 7 _ |a 1097-0193
|2 ISSN
024 7 _ |a 2128/28089
|2 Handle
024 7 _ |a altmetric:101378410
|2 altmetric
024 7 _ |a 33666305
|2 pmid
024 7 _ |a WOS:000625860700001
|2 WOS
037 _ _ |a FZJ-2021-02894
082 _ _ |a 610
100 1 _ |a Hawkins, Peter C. T.
|0 0000-0002-2256-1648
|b 0
|e Corresponding author
245 _ _ |a The effect of risperidone on reward‐related brain activity is robust to drug‐induced vascular changes
260 _ _ |a New York, NY
|c 2021
|b Wiley-Liss
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1625910820_19248
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Dopamine (DA) mediated brain activity is intimately linked to reward-driven cerebralresponses, while aberrant reward processing has been implicated in several psychiatricdisorders. fMRI has been a valuable tool in understanding the mechanism by which DAmodulators alter reward-driven responses and how they may exert their therapeuticeffect. However, the potential effects of a pharmacological compound on aspects ofneurovascular coupling may cloud the interpretability of the BOLD contrast. Here, weassess the effects of risperidone on reward driven BOLD signals produced by rewardanticipation and outcome, while attempting to control for potential drug effects onregional cerebral blood flow (CBF) and cerebrovascular reactivity (CVR). Healthy malevolunteers (n = 21) each received a single oral dose of either 0.5 mg, 2 mg of risperi-done or placebo in a double-blind, placebo-controlled, randomised, three-period cross-over study design. Participants underwent fMRI scanning while performing the widelyused Monetary Incentive Delay (MID) task to assess drug impact on reward function.Measures of CBF (Arterial Spin Labelling) and breath-hold challenge induced BOLD sig-nal changes (as a proxy for CVR) were also acquired and included as covariates. Risperi-done produced divergent, dose-dependent effects on separate phases of rewardprocessing, even after controlling for potential nonneuronal influences on the BOLDsignal. These data suggest the D2 antagonist risperidone has a wide-ranging influenceon DA-mediated reward function independent of nonneuronal factors. We also illus-trate that assessment of potential vascular confounds on the BOLD signal may beadvantageous when investigating CNS drug action and advocate for the inclusion ofthese additional measures into future study designs.
536 _ _ |a 5253 - Neuroimaging (POF4-525)
|0 G:(DE-HGF)POF4-5253
|c POF4-525
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de
700 1 _ |a Zelaya, Fernando O.
|0 P:(DE-HGF)0
|b 1
700 1 _ |a O'Daly, Owen
|0 P:(DE-HGF)0
|b 2
700 1 _ |a Holiga, Stefan
|0 P:(DE-HGF)0
|b 3
700 1 _ |a Dukart, Jürgen
|0 P:(DE-Juel1)177727
|b 4
|u fzj
700 1 _ |a Umbricht, Daniel
|0 P:(DE-HGF)0
|b 5
700 1 _ |a Mehta, Mitul A.
|0 P:(DE-HGF)0
|b 6
773 _ _ |a 10.1002/hbm.25400
|g Vol. 42, no. 9, p. 2766 - 2777
|0 PERI:(DE-600)1492703-2
|n 9
|p 2766 - 2777
|t Human brain mapping
|v 42
|y 2021
|x 1097-0193
856 4 _ |u https://juser.fz-juelich.de/record/893882/files/hbm.25400.pdf
|y OpenAccess
909 C O |o oai:juser.fz-juelich.de:893882
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Forschungszentrum Jülich
|0 I:(DE-588b)5008462-8
|k FZJ
|b 4
|6 P:(DE-Juel1)177727
913 1 _ |a DE-HGF
|b Key Technologies
|l Natural, Artificial and Cognitive Information Processing
|1 G:(DE-HGF)POF4-520
|0 G:(DE-HGF)POF4-525
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-500
|4 G:(DE-HGF)POF
|v Decoding Brain Organization and Dysfunction
|9 G:(DE-HGF)POF4-5253
|x 0
914 1 _ |y 2021
915 _ _ |a Creative Commons Attribution CC BY 4.0
|0 LIC:(DE-HGF)CCBY4
|2 HGFVOC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2021-01-27
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b HUM BRAIN MAPP : 2019
|d 2021-01-27
915 _ _ |a DEAL Wiley
|0 StatID:(DE-HGF)3001
|2 StatID
|d 2021-01-27
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2021-01-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2021-01-27
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2021-01-27
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2021-01-27
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0320
|2 StatID
|b PubMed Central
|d 2021-01-27
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
|d 2021-01-27
|w ger
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2021-01-27
920 _ _ |l yes
920 1 _ |0 I:(DE-Juel1)INM-7-20090406
|k INM-7
|l Gehirn & Verhalten
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-Juel1)INM-7-20090406
980 1 _ |a FullTexts

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21